These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12818936)

  • 61. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

  • 62. [Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer].
    Ono C; Yamagami M; Kamatani R; Yamamoto M; Mukouyama T; Sugimoto M; Suzuki T; Kamo N; Seki N; Eguchi K; Ikeda T
    Gan To Kagaku Ryoho; 2012 May; 39(5):777-81. PubMed ID: 22584330
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.
    Nisticò C; Bria E; Cuppone F; Carpino A; Ferretti G; Vitelli G; Sperduti I; Calabretta F; Toglia G; Tomao S; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Feb; 18(2):227-32. PubMed ID: 17159609
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Epirubicin hydrochloride.
    Dolbey C
    Clin J Oncol Nurs; 2002; 6(4):247-8. PubMed ID: 12087624
    [No Abstract]   [Full Text] [Related]  

  • 67. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M; Nafee N; Saad H; Kazem A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
    Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
    Hatake K; Miura Y
    Lancet; 1996 May; 347(9013):1485. PubMed ID: 8676653
    [No Abstract]   [Full Text] [Related]  

  • 71. Hypersensitivity reaction to epirubicin.
    Cassidy J; Rankin EM
    Med Oncol Tumor Pharmacother; 1989; 6(4):297-8. PubMed ID: 2615533
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epirubicin as adjuvant therapy in breast cancer.
    Earl H; Iddawela M
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Toxicity associated with epirubicin treatments in a large case series of dogs.
    Marrington AM; Killick DR; Grant IA; Blackwood L
    Vet Comp Oncol; 2012 Jun; 10(2):113-23. PubMed ID: 22236353
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.
    Havsteen H; Bertelsen K; Gadeberg CC; Jacobsen A; Kamby C; Sandberg E; Sengeløv L
    Gynecol Oncol; 1996 Nov; 63(2):210-5. PubMed ID: 8910629
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Neoadjuvant intraarterial chemotherapy with dose intensification in locally advanced breast cancer].
    Takatsuka Y; Shin E; Fukuda K; Mishima H; Tono T; Yagyuu T; Kobayashi K; Kikkawa N
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1546-8. PubMed ID: 7574755
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sino-atrial block in typhoid fever.
    Mathur SL
    J Assoc Physicians India; 1990 Mar; 38(3):243-4. PubMed ID: 2391309
    [No Abstract]   [Full Text] [Related]  

  • 80. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.